The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancer

The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancer - The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017350

Enrollment

Registered

2015-04-30

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced esophageal cancer

Interventions

Radiation therapy Fluorouracil(5-FU) Cisplatin(CDDP) Alpha-Beta T-cell Therapy immature Dendritic cells Therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patient with Locally advanced esophageal cancer (T2-3N0-1M0-1a, StageII-IVA except T4; UICC) (2) Patients can be conducted apheresis before chemotherapy (3) Patient age of 20 to 80 years (4) Patient with performance status 0-2 (5) Patient has more than three months of expected life time (6) Patients with no bone-marrow, liver, and renal dysfunction (7) Patient agrees to participate in this study with informed consent

Exclusion criteria

Exclusion criteria: (1) Patient with interstitial pneumonia (2) Patient who received cancer immunotherapy (3) Patient with active autoimmune disease (4) Patient with active heart disease (5) Patient with uncontrollable infectious diseases (6) Patient with serious drug allergy (7) Patient with uncontrollable diabetes mellitus (8) Patient with active multiple malignancies (9) Patient with continuous use of systemic administration of steroids (10) Patient with severe psychological disorders (11) Patient in pregnancy (12) Patient positive for HIV or HTLV-1 (13) Current participation in other drug clinical trials. (excluding the study, which doesn't need intervention) (14) Patients who are inadequate to enter this study due to the other reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Safety Local control rate at one year	—

Secondary

Measure	Time frame
overall survival period overall survival rate Distant metastasis-free survival rete QOL immunological parameters	—

Countries

Japan

Contacts

Public ContactShin-ei Noda

Gunma University Department of Radiation Oncology, Gunma University Graduate School of Medicine

snoda@gunma-u.ac.jp027-220-8383

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026